Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
Merck's COVID-19 pill effective against Omicron in lab studies
By REUTERS
04/26/2024 06:42 PM
By REUTERS
04/26/2024 05:24 PM
By REUTERS
04/26/2024 04:53 PM
By REUTERS
04/26/2024 03:10 PM
By REUTERS
04/26/2024 02:13 PM
By REUTERS
04/26/2024 01:09 PM